BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/25/2014 12:36:00 PM | Browse: 485 | Download: 296
Publication Name World Journal of Radiology
Manuscript ID 7637
Country/Territory Germany
Received
2013-11-27 15:46
Peer-Review Started
2013-11-27 21:38
To Make the First Decision
2014-03-12 16:58
Return for Revision
2014-03-20 20:09
Revised
Second Decision
2014-05-16 17:34
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-05-16 17:53
Articles in Press
2014-05-23 12:36
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-07-11 15:44
Publish the Manuscript Online
2014-07-31 11:53
ISSN 1949-8470 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Radiology, Nuclear Medicine and Medical Imaging
Manuscript Type Minireviews
Article Title Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters
Manuscript Source Invited Manuscript
All Author List Hinrich A Wieder, Michael Lassmann, Martin S Allen-Auerbach, Johannes Czernin and Ken Herrmann
Funding Agency and Grant Number
Corresponding Author Hinrich A Wieder, MD, Department of Radiology, Zentrum für Radiologie und Nuklearmedizin, Zentrum für Radiologie und Nuklearmedizin, Von-Werth-Stra?e 5, 41515 Grevenbroich, Germany. h@wieder.de
Key Words Radium; Bone targeted radiopharmaceuticals; Alpha emitters
Core Tip The incidence rate of prostate cancer worldwide is high. Ninety percent of patients dying of prostate cancer have bone metastases with varying symptoms which are significantly impairing their quality of life. 223Radium is the first therapeutic that results in a survival benefit for patients with bone metastatic, castrate resistant prostate cancer. 223Radium was also associated with low myelosuppression rates and fewer adverse events.This article provides an overview of the pre-clinical and clinical trials with 223Radium.
Publish Date 2014-07-31 11:53
Citation Wieder HA, Lassmann M, Allen-Auerbach M, Czernin J, Herrmann K. Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters. World J Radiol 2014; 6(7): 480-485
Url http://www.wjgnet.com/1949-8470/full/v6/i7/480.htm
DOI http://dx.doi.org/10.4329/wjr.v6.i7.480
Full Article (PDF) WJR-6-480.pdf
Full Article (Word) WJR-6-480.doc
Manuscript File 7637-Review.docx
Answering Reviewers 7637-Answering reviewers.pdf
Copyright License Agreement 7637-Copyright assignment.pdf
Peer-review Report 7637-Peer review(s).pdf
Scientific Editor Work List 7637-Scientific editor work list.pdf